Clinic
University of Texas M. D. Anderson Cancer Center
University of Texas M. D. Anderson Cancer Center was paid $4.70M by Medicaid between Jan 2019 and Nov 2024, across 213 billing codes. Its largest line is J9271, Injection, pembrolizumab, 1 mg — 50% of everything it billed.
33Billing provider infoUNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER
HOUSTON, TX 77030
HOUSTON, TX 77030
33aNPI1174582050assigned 03/21/2006
33bProvider typeMulti-Specialty Clinic/Center
28Total paid$4.70M
24GClaims336,361
24DCodes billed213
24AFirst – last monthJan 2019 – Nov 2024
Compared with peers
Next to other Multi-Specialty Clinic/Center providers in Texas
Rank by total paid#9 of 86
Median peer was paid$191K
This provider vs. median25×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 6,390 | $31K | |
| 2020 | 3,551 | $9K | |
| 2021 | 86,554 | $1.20M | |
| 2022 | 94,950 | $1.57M | |
| 2023 | 87,545 | $1.08M | |
| 2024incomplete | 57,371 | $808K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 50% | 763 | 647 | $2.37M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 8.5% | 6,790 | 4,135 | $402K |
| 78815 | Positron emission tomography (PET) for limited area imaging | 7.8% | 1,286 | 1,269 | $365K |
| 77386 | 2.9% | 480 | 51 | $136K | |
| 80053 | Comprehensive metabolic panel | 2.6% | 17,354 | 12,397 | $122K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.6% | 31,110 | 18,209 | $122K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 2,554 | 2,505 | $92K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.6% | 462 | 457 | $77K |
| 77334 | 1.5% | 312 | 240 | $73K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.5% | 1,047 | 1,027 | $70K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.2% | 3,418 | 3,375 | $55K |
| 77300 | 1.1% | 279 | 249 | $50K |
201 more codes
| J0897 | Injection, denosumab, 1 mg | <1% | 142 | $47K |
| 80050 | General health panel | <1% | 160 | $42K |
| 96417 | <1% | 1,863 | $40K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,990 | $35K |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion | <1% | 349 | $35K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 509 | $29K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,658 | $26K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,104 | $25K |
| 70491 | <1% | 762 | $25K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 19,115 | $21K |
| 88341 | <1% | 996 | $21K | |
| 76641 | <1% | 424 | $18K | |
| J9299 | Injection, nivolumab, 1 mg | <1% | 20 | $17K |
| 77066 | Tomosynthesis, mammo | <1% | 272 | $17K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,807 | $16K |
| 83735 | <1% | 16,125 | $15K | |
| 88342 | <1% | 1,102 | $12K | |
| 77470 | <1% | 36 | $11K | |
| 76536 | <1% | 473 | $11K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 964 | $11K |
| 71250 | <1% | 572 | $11K | |
| 74178 | <1% | 356 | $11K | |
| 72197 | <1% | 146 | $11K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 910 | $10K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,066 | $10K |
| 78306 | <1% | 240 | $10K | |
| 80069 | <1% | 1,819 | $7K | |
| 83615 | <1% | 10,069 | $7K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,049 | $7K |
| 96367 | <1% | 2,202 | $7K | |
| 96402 | <1% | 433 | $6K | |
| 77336 | <1% | 1,003 | $6K | |
| 85027 | <1% | 4,393 | $6K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,717 | $6K |
| 76604 | <1% | 338 | $6K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 138 | $6K |
| 86885 | <1% | 4,549 | $6K | |
| Q3014 | Telehealth originating site facility fee | <1% | 1,839 | $6K |
| 86900 | <1% | 7,307 | $6K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,652 | $6K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 522 | $5K |
| 72156 | <1% | 13 | $5K | |
| 82248 | <1% | 13,914 | $5K | |
| 86901 | <1% | 6,536 | $4K | |
| 0001A | <1% | 354 | $4K | |
| 84550 | <1% | 6,477 | $4K | |
| 36430 | <1% | 418 | $4K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 317 | $4K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,716 | $4K |
| 85007 | <1% | 3,951 | $4K | |
| 86850 | <1% | 1,393 | $3K | |
| 81455 | <1% | 72 | $3K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 50 | $3K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,061 | $3K |
| 0002A | <1% | 297 | $3K | |
| 84439 | <1% | 3,904 | $3K | |
| 84100 | <1% | 11,719 | $3K | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 12 | $3K |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 272 | $3K |
| 82784 | <1% | 2,546 | $3K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 1,461 | $2K |
| 82378 | <1% | 1,540 | $2K | |
| 94760 | <1% | 857 | $2K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,170 | $2K |
| G0384 | Level 5 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 310 | $2K |
| 86920 | <1% | 288 | $2K | |
| 88321 | <1% | 587 | $2K | |
| 85610 | <1% | 2,671 | $2K | |
| 85730 | <1% | 1,363 | $2K | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 103 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,730 | $2K |
| 72157 | <1% | 13 | $1K | |
| 83880 | <1% | 287 | $1K | |
| 72158 | <1% | 13 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,739 | $1K |
| 87631 | <1% | 34 | $1K | |
| 71045 | Radiologic examination, chest; single view | <1% | 280 | $1K |
| 88173 | <1% | 116 | $1K | |
| 81001 | <1% | 1,844 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,452 | $1K |
| 92060 | <1% | 14 | $1K | |
| 86304 | <1% | 754 | $1K | |
| 82565 | <1% | 4,686 | $1K | |
| 36591 | <1% | 670 | $1K | |
| 84460 | <1% | 3,226 | $1K | |
| 86300 | <1% | 599 | $1K | |
| 82247 | <1% | 2,953 | $996.15 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 888 | $945.49 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 79 | $942.48 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 193 | $937.80 |
| 88307 | <1% | 52 | $936.70 | |
| 74183 | <1% | 14 | $929.30 | |
| 82728 | <1% | 695 | $928.88 | |
| 86803 | <1% | 643 | $919.69 | |
| 80051 | <1% | 1,246 | $883.30 | |
| 84075 | <1% | 2,426 | $867.24 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,199 | $860.65 |
| 85097 | <1% | 40 | $830.97 | |
| 92133 | <1% | 13 | $813.94 | |
| 77080 | <1% | 193 | $811.98 | |
| 83690 | <1% | 794 | $810.31 | |
| 88172 | <1% | 37 | $809.91 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 438 | $788.21 |
| 77065 | Tomosynthesis, mammo | <1% | 25 | $784.73 |
| 36415 | Collection of venous blood by venipuncture | <1% | 22,168 | $744.64 |
| 82150 | <1% | 805 | $729.05 | |
| 84155 | <1% | 2,142 | $719.42 | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 12 | $673.99 |
| 84484 | <1% | 274 | $667.78 | |
| 94010 | <1% | 39 | $627.58 | |
| 84403 | <1% | 776 | $624.40 | |
| 94729 | <1% | 62 | $598.56 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 233 | $584.31 |
| 80076 | <1% | 85 | $512.82 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 474 | $494.61 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,277 | $488.79 |
| 87040 | <1% | 166 | $485.43 | |
| 80061 | Lipid panel | <1% | 804 | $457.57 |
| 82533 | <1% | 112 | $444.38 | |
| 82550 | <1% | 592 | $438.42 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 964 | $437.03 |
| 82232 | <1% | 1,089 | $435.37 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,222 | $411.30 |
| 84450 | <1% | 1,434 | $405.10 | |
| 84480 | <1% | 280 | $365.10 | |
| 84520 | <1% | 1,780 | $361.79 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,247 | $361.58 |
| 88237 | <1% | 25 | $350.17 | |
| 84153 | <1% | 863 | $324.16 | |
| 97162 | <1% | 12 | $320.56 | |
| 83521 | <1% | 817 | $310.73 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,569 | $282.28 |
| 87340 | <1% | 300 | $280.59 | |
| 82570 | <1% | 158 | $268.75 | |
| 82607 | <1% | 223 | $254.10 | |
| 81025 | <1% | 91 | $245.13 | |
| 86704 | <1% | 164 | $243.24 | |
| 84165 | <1% | 1,013 | $233.62 | |
| 86334 | <1% | 868 | $225.24 | |
| 84156 | <1% | 984 | $210.24 | |
| 86140 | <1% | 350 | $208.39 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,519 | $197.30 |
| 82310 | <1% | 822 | $186.71 | |
| 94726 | <1% | 38 | $185.00 | |
| 86301 | <1% | 149 | $181.89 | |
| 88108 | <1% | 17 | $173.61 | |
| 84466 | <1% | 162 | $151.87 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 590 | $144.20 |
| J3490 | Unclassified drugs | <1% | 170 | $141.94 |
| 87077 | <1% | 172 | $133.31 | |
| 88185 | <1% | 28 | $122.15 | |
| 83883 | <1% | 531 | $114.20 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,127 | $112.30 |
| 82947 | <1% | 813 | $105.49 | |
| 82040 | <1% | 648 | $104.94 | |
| 83970 | <1% | 28 | $102.31 | |
| 83540 | <1% | 193 | $98.69 | |
| 81050 | <1% | 590 | $90.98 | |
| 86335 | <1% | 278 | $83.92 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,751 | $82.25 |
| 81003 | <1% | 273 | $74.67 | |
| 36592 | <1% | 1,262 | $68.37 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 240 | $66.32 |
| 86923 | <1% | 20 | $62.22 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 240 | $59.73 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 16 | $50.22 |
| 82553 | <1% | 34 | $48.50 | |
| 96415 | <1% | 1,365 | $46.40 | |
| 97750 | <1% | 14 | $45.37 | |
| 84166 | <1% | 396 | $44.94 | |
| 82105 | <1% | 83 | $41.57 | |
| 87186 | <1% | 51 | $36.35 | |
| 82746 | <1% | 42 | $35.81 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 69 | $35.50 |
| 84432 | <1% | 65 | $30.73 | |
| 87070 | <1% | 46 | $28.96 | |
| 84481 | <1% | 13 | $28.46 | |
| 83605 | <1% | 28 | $28.18 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 941 | $22.39 |
| 84436 | <1% | 12 | $11.54 | |
| 85379 | <1% | 12 | $8.55 | |
| 86800 | <1% | 39 | $3.71 | |
| 82962 | <1% | 2,339 | $3.57 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 12 | $0.98 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | <1% | 4,552 | $0.01 |
| 0003A | 0% | 19 | $0.00 | |
| 82523 | 0% | 13 | $0.00 | |
| 87497 | 0% | 65 | $0.00 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 914 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 41 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 19 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 53 | $0.00 |
| 96376 | 0% | 27 | $0.00 | |
| 87205 | 0% | 14 | $0.00 | |
| 88363 | 0% | 12 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 16 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 27 | $0.00 |
| 96368 | 0% | 17 | $0.00 | |
| 88184 | 0% | 29 | $0.00 | |
| C9399 | Unclassified drugs or biologicals | 0% | 12 | $0.00 |
| 86706 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFLORES, MIRIAM (VICE PRESIDENT, REVENUE CYCLE)
| Provider | Location | Paid |
|---|---|---|
| Physicians Referral Service | Houston, TX | $266K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.